Importance of high-density lipoprotein cholesterol control during pravastatin treatment in hypercholesterolemic Japanese with type 2 diabetes mellitus: A post hoc analysis of MEGA study

Diabetes Research and Clinical Practice

Volumn 100, Issue 2, 2013, Pages

  Nishimura, Rimei ^a   Sone, Hirohito ^b   Nakagami, Tomoko ^c   Tajima, Naoko ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NIIGATA UNIVERSITY   (Japan)

^c TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Cardiovascular risk; Diabetes; HDL C; LDL C; Statin

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN;

ARTICLE; CARDIOVASCULAR RISK; CLINICAL STUDY; CONTROLLED STUDY; DIABETIC PATIENT; DIET THERAPY; FEMALE; FOLLOW UP; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT EDUCATION; POST HOC ANALYSIS; RISK REDUCTION;

ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PRAVASTATIN;

EID: 84878348555     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2013.02.003     Document Type: Article

References (9)

1. Baigent C., Keech A., Kearney P.M., Blackwell L., Buck G., Pollicino C., et al. Cholesterol treatment trialists' (CTT) collaborators: efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267-1278.
2. Law M.R., Wald N.J., Rudnicka A.R. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003, 326(June):1423.
3. Nakamura H., Arakawa K., Itakura H., Kitabatake A., Goto Y., Toyota T., et al. MEGA study group: primary prevention of cardiovascular disease with pravastatin in Japan (MEGA study): a prospective randomised controlled trial. Lancet 2006, 368:1155-1163.
4. Barter P.J., Caulfield M., Eriksson M., Grundy S.M., Kastelein J.J., Komajda M., et al. ILLUMINATE investigators: effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007, 357:2109-2122.
5. Rhainds D., Arsenault B.J., Brodeur M.R., Tardif J.C. An update on the clinical development of dalcetrapib (RO4607381), a cholesteryl ester transfer protein modulator that increases HDL cholesterol levels. Future Cardiol 2012, 8:513-531.
6. Windler E. What is the consequence of an abnormal lipid profile in patients with type 2 diabetes or the metabolic syndrome?. Atheroscler Suppl 2005, 6:11-14.
7. Tajima N., Kurata H., Nakaya N., et al. Pravastatin reduces the risk for cardiovascular disease in Japanese hypercholesterolemic patients with impaired fasting glucose or diabetes: diabetes subanalysis of the management of elevated cholesterol in the primary prevention group of adult Japanese (MEGA) study. Atherosclerosis 2008, 199:455-462.
8. National Cholesterol Education Program: Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATP II), US Department of Health and Human Services, Washington, DC, 1993.
9. Sviridov D., Nestel P., Watts G. Statins and metabolism of high density lipoprotein. Cardiovasc Hematol Agents Med Chem 2007, 5:215-221.